
Solid Biosciences (SLDB) Stock Forecast & Price Target
Solid Biosciences (SLDB) Analyst Ratings
Bulls say
Solid Biosciences Inc is positioned favorably due to the successful outcomes observed in its cardiac measures, where stable-to-improved left ventricular ejection fraction (LVEF) was reported, particularly among a subset of patients with previously low LVEF. The company has enhanced its program's probability of success to 60% following consistent positive data, indicating a potential for attractive market positioning in the future. Furthermore, with a projected year-end cash balance of $188 million and ongoing advancements in the Phase 3 IMPACT DUCHENNE trial, Solid Biosciences appears well-equipped to sustain its research initiatives and navigate regulatory pathways effectively.
Bears say
Solid Biosciences Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily due to potential safety issues and regulatory hurdles for its lead product, SGT-003, aimed at treating Duchenne muscular dystrophy. The company's projections for market penetration and sales may experience dramatic downward revisions if the drug fails to secure regulatory approval or faces manufacturing constraints, impacting its ability to capitalize on expected growth opportunities. Additionally, the inherent risks associated with clinical development and competition in the biotechnology sector further exacerbate concerns related to the company's financial stability and growth potential.
This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Solid Biosciences (SLDB) Analyst Forecast & Price Prediction
Start investing in Solid Biosciences (SLDB)
Order type
Buy in
Order amount
Est. shares
0 shares